Cover Image
市場調查報告書

全球皰疹市場

Global Herpes Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 320939
出版日期 內容資訊 英文 67 Pages
訂單完成後即時交付
價格
Back to Top
全球皰疹市場 Global Herpes Market 2014-2018
出版日期: 2014年12月03日 內容資訊: 英文 67 Pages
簡介

通常皰疹,分為口腔皰疹(單純皰疹)和生殖器皰疹(生殖器皰疹)2種,口腔皰疹的原因為HSV-1,生殖器皰疹的原因為HSV-1和HSV-2。全球皰疹市場,從2013年到2018年之間,預計以10.14%的年複合成長率擴大。

本報告提供全球皰疹市場現狀分析與今後的預測、罹患率與盛行率、產品類型、各病毒類型趨勢、主要治療藥的評估、市場成長要素與課題、主要供應商分析等。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品
    • 產品簡介

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場規模與預測

第7章 上市產品的評估

  • 波特的五力分析

第8章 罹患率和盛行率

  • 美國
  • 英國

第9章 皰疹的診斷

第10章 各產品類型的市場分類

第11章 各病毒類型的市場區隔

第12章 主要治療藥的市場評估

  • Zovirax
  • Valtrex

第13章 地理區隔

第14章 購買標準

第15章 市場成長因素

第16章 成長因素與其影響

第17章 市場課題

第18章 成長因素與課題的影響

第19章 市場趨勢

第20章 趨勢與其影響

第21章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
  • 其他卓越供應商

第22章 主要供應商分析

  • Gilead Sciences
  • GlaxoSmithKline
  • Merck & Co. Inc.
  • Novartis

第23章 相關報告

目錄
Product Code: IRTNTR4662

About Herpes

Generally, herpes covers two different diseases: oral herpes, also known as cold sores and genital herpes. While oral herpes affects the area around the mouth, genital herpes affects area around the genitals. The HSV-1 causes oral herpes; both HSV-1 and HSV-2 cause genital herpes. HSV is a contagious virus that spread through contact. At present, there is no cure for herpes, however, treatments can help reduce the pain and decrease healing period.

TechNavio's analysts forecast the Global Herpes market to grow at a CAGR of 10.14 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Herpes market for the period 2013-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs and vaccines used in the treatment and prevention of herpes simplex, herpes zoster and CMV infections that are available in the market.

The report also presents the vendor landscape and a corresponding detailed analysis of the vendors in the Global Herpes market. In addition, the report discusses the major drivers that influence the growth of the market and outlines the challenges faced by the vendors and the market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Gilead Sciences
  • GSK
  • Merck
  • Novartis

Other Prominent Vendors

  • Agenus
  • AiCuris
  • aRigen Pharmaceuticals
  • Astellas Pharma
  • CytoGenix
  • Epiphany Biosciences
  • F. Hoffmann-La Roche
  • Genocea Biosciences
  • NanoBio

Market Driver

  • Significant Unmet Needs
  • For a full, detailed list, view our report

Market Challenge

  • Increasing Generic Competition
  • For a full, detailed list, view our report

Market Trend

  • Promising New Launches
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
    • 03.2.1. Product Profiles

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast

07. Competitive Assessment of Marketed Products

  • 07.1. Five Forces Analysis

08. Rate of Incidence and Prevalence

    • 08.1.1. US
    • 08.1.2. UK

09. Diagnosis of Herpes

10. Market Segmentation by Product Type

11. Market Segmentation by Type of Virus

12. Market Assessment of Top Drugs

  • 12.1. Zovirax
    • 12.1.1. Sales
  • 12.2. Valtrex
    • 12.2.1. Sales

13. Geographical Segmentation

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

  • 21.1. Competitive Scenario
    • 21.1.1. Key News
    • 21.1.2. Mergers and Acquisitions
  • 21.2. Market Share Analysis 2013
  • 21.3. Other Prominent Vendors

22. Key Vendor Analysis

  • 22.1. Gilead Sciences
    • 22.1.1. Key Facts
    • 22.1.2. Business Overview
    • 22.1.3. Geographical Segmentation by Revenue 2013
    • 22.1.4. Recent Developments
    • 22.1.5. SWOT Analysis
  • 22.2. GlaxoSmithKline
    • 22.2.1. Key Facts
    • 22.2.2. Business Overview
    • 22.2.3. Business Segmentation
    • 22.2.4. Business Segmentation by Revenue 2012 and 2013
    • 22.2.5. Sales by Geography
    • 22.2.6. Pipeline Products
    • 22.2.7. Business Strategy
    • 22.2.8. Key Information
    • 22.2.9. SWOT Analysis
  • 22.3. Merck & Co. Inc.
    • 22.3.1. Key Facts
    • 22.3.2. Business Overview
    • 22.3.3. Business Segmentation by Revenue 2013
    • 22.3.4. Business Segmentation by Revenue 2012 and 2013
    • 22.3.5. Sales by Geography
    • 22.3.6. Business Strategy
    • 22.3.7. Key Developments
    • 22.3.8. SWOT Analysis
  • 22.4. Novartis
    • 22.4.1. Key Facts
    • 22.4.2. Business Overview
    • 22.4.3. Business Segmentation by Revenue 2013
    • 22.4.4. Business Segmentation by Revenue 2012 and 2013
    • 22.4.5. Sales by Geography
    • 22.4.6. Business Strategy
    • 22.4.7. Key Developments
    • 22.4.8. SWOT Analysis

23. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Herpes Market 2013-2018 (US$ billion)
  • Exhibit 3: Diagnosis of Herpes
  • Exhibit 4: Global Herpes Market Segmentation by Type
  • Exhibit 5: GSK's Zovirax Revenue 2010-2013 (US$ million)
  • Exhibit 6: GSK's Valtrex Revenue 2010-2013 (US$ million)
  • Exhibit 7: Global Herpes Market by Geographical Segmentation 2013
  • Exhibit 8: Gilead Sciences: Geographical Segmentation by Revenue 2013
  • Exhibit 9: GlaxoSmithKline: Business Segmentation 2013
  • Exhibit 10: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 11: GlaxoSmithKline: Sales by Geography 2013
  • Exhibit 12: GlaxoSmithKline: Pipeline Products 2013
  • Exhibit 13: Merck & Co. Inc.: Business Segmentation by Revenue 2013
  • Exhibit 14: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 15: Merck & Co. Inc.: Sales by Geography 2013
  • Exhibit 16: Novartis: Business Segmentation by Revenue 2013
  • Exhibit 17: Novartis: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 18: Novartis: Sales by Geography 2013
Back to Top